110333-07-8

Basic information

• Product Name: 5-Chloromethylquinoline
• Synonyms: 5-Chloromethylquinoline;Quinoline, 5-(chloromethyl)-
• CAS NO: 110333-07-8
• Molecular Formula: C₁₀H₈ClN
• Molecular Weight: 177.63022
• Mol File: 110333-07-8.mol

Chemical Properties

• Melting Point: 90-90.5 °C
• Boiling Point: 310.6±17.0 °C(Predicted)
• Appearance: /
• Density: 1.229±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.55±0.12(Predicted)
• CAS DataBase Reference: 5-Chloromethylquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloromethylquinoline(110333-07-8)
• EPA Substance Registry System: 5-Chloromethylquinoline(110333-07-8)

Safety Data

• Hazardous Substances Data: 110333-07-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
5-Chloromethylquinoline is used as a precursor in the synthesis of various pharmaceuticals due to its antimicrobial, anti-inflammatory, and anticancer properties. Its versatile reactivity and bioactivity make it a valuable component in the development of new drugs.
Used in Agrochemical Production:
In the agrochemical industry, 5-Chloromethylquinoline is utilized as a key intermediate for the production of various agrochemicals, leveraging its biocidal properties to protect crops from pests and diseases.
Used in Organic Synthesis:
5-Chloromethylquinoline serves as a building block in organic synthesis, where its unique structure and functional groups contribute to the creation of a wide range of chemical compounds for various applications.
It is crucial to handle 5-Chloromethylquinoline with care due to its potential health hazards if not used properly, emphasizing the need for proper safety measures during its application in different industries.

Upstream product

• 16178-42-0 quinolin-5-ylmethanol 
• 22934-41-4 quinoline-5-carbaldehyde 

Downstream Products

• 1146365-37-8 5,5'-(4-(trifluoromethyl)benzylazanediyl)bis-(methylene)diquinoline 
• 1421365-49-2 C₂₁H₁₆ClN₃O₃ 
• 555155-04-9 2-(quinolin-5-yl)acetonitrile 

Relevant articles and documents

PYRIDAZINONES AND METHODS OF USE THEREOF

Disclosed are compounds according to Formula (A), and related tautomers and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (A).

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ～150. This partitioning onto the target protein is anticipated to allow therapeutic concentrations to be achieved in the red blood cell at low plasma concentrations. GBT440 (36) is in Phase 3 clinical trials for the treatment of sickle cell disease (NCT03036813).

Discovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferase

N-Myristoyltransferase (NMT) represents an attractive drug target in parasitic infections such as malaria due to its genetic essentiality and amenability to inhibition by drug-like small molecules. Scaffold simplification from previously reported inhibitors containing bicyclic cores identified phenyl derivative 3, providing a versatile platform to study the effects of substitution on the scaffold, which yielded pyridyl 19. This molecule exhibited improved enzyme and cellular potency, and reduced lipophilicity compared to inhibitor 3. Further structure-based inhibitor design led to the discovery of 30, the most potent inhibitor in this series, which showed single-digit nM enzyme affinity and sub-μM anti-plasmodial activity.

Discovery of a new family of bis-8-hydroxyquinoline substituted benzylamines with pro-apoptotic activity in cancer cells: Synthesis, structure-activity relationship, and action mechanism studies

Bis-8-hydroxyquinoline substituted benzylamines have been synthesized and screened for their antitumor activity on KB3 cell line model. Synthesis of this series of new analogues was accomplished using a one pot specific methodology which allows the synthesis of both bis- and mono-8-hydroxyquinoline substituted benzylamines. Among the synthesized compounds two compounds (4a and 5a), respectively, named JLK 1472 and JLK 1486, were particularly potent on KB3 cell line. Their CC50 values being, respectively, 2.6 and 1.3 nM. Screened on a panel of cell lines showing various phenotype alterations, both compounds were found inactive on some cell lines such as PC3 (prostate cell line) and SF268 (neuroblastoma cell line) while highly active on other different cell lines. Mechanistic studies reveal that these two analogues did not affect tubulin and microtubules neither they exert a proteasomal inhibition effect. In contrast 4a and 5a activate specifically caspase 3/7 and not caspase 8 and 9, suggesting that their biological target should be located upstream from caspase 3/7. Moreover their cytotoxic effect is potentiated by the pro-apoptotic effects of TRAIL.